Another CDR cyclic peptide formulation (Rb9) also exhibited immunomodulatory effects on DCs by disturbing MIF/CD74 axis, boosting melanoma immunogenicity, when treating advanced lung metastasis [124]. Here, MIF is linked to melanoma.